C1 Pill: white, round, 4mm

In the placebo-controlled study, the most common AEs were generally transient and mild to moderate in intensity. Table 1 presents treatment-emergent adverse events reported by greater than or equal to 9% of patients in the tadalafil tablets 40 mg group and occurring more frequently than with placebo. The following adverse reactions have been identified during post-approval use of tadalafil. The list does not include adverse events that are reported from clinical trials and that are listed elsewhere in this section. Cardiovascular and cerebrovascular — Serious cardiovascular events, including myocardial infarction, sudden cardiac death, stroke, chest pain, palpitations, and tachycardia, have been reported postmarketing in temporal association with the use of tadalafil [see Contraindications (4.1)]. It is not possible to determine whether these events are related directly to tadalafil, to sexual activity, to the patient’s underlying cardiovascular disease, to a combination of these factors, or to other factors. Body as a whole — Hypersensitivity reactions including urticaria, Stevens–Johnson syndrome, and exfoliative dermatitis Nervous — Migraine, seizure and seizure recurrence, and transient global amnesia Ophthalmologic — Visual field defect, retinal vein occlusion, retinal artery occlusion, and NAION [see Warnings and Precautions (5.3) and Patient Counseling Information (17)]. Otologic — Cases of sudden decrease or loss of hearing have been reported postmarketing in temporal association with the use of PDE5 inhibitors, including tadalafil. It is not possible to determine whether these reported events are related directly to the use of tadalafil, to the patient’s underlying risk factors for hearing loss, a combination of these factors, or to other factors [see Warnings and Precautions (5.4) and Patient Counseling Information (17)].

Adverse effects

Urogenital — Priapism [see Warnings and Precautions (5.6)]. 7 DRUG INTERACTIONS 7.1 NitratesAdministration of nitrates within 48 hours after the last dose of tadalafil is contraindicated [see Contraindications (4.1)].7.2 Alpha-BlockersPDE5 inhibitors, including tadalafil tablets, and alpha–adrenergic blocking agents are both vasodilators with blood-pressure-lowering effects.

Product	Dosage	Quantity + Bonus	Price
Cialis Generic	20mg	10 Pills	31.49€ 29.99€	Buy
Cialis Professional	40mg	180 + 4 Pills	618.23€ 588.79€	Buy
Cialis Original	20mg	4 Pills	41.99€ 39.99€	Buy
Cialis Generic	60mg	60 + 4 Pills	145.06€ 138.15€	Buy
Cialis Professional	20mg	120 + 4 Pills	291.68€ 277.79€	Buy
Cialis Generic	5mg	180 + 10 Pills	159.65€ 152.05€	Buy
Cialis Generic	60mg	180 + 10 Pills	313.11€ 298.20€	Buy
Cialis Generic	10mg	90 + 6 Pills	146.17€ 139.21€	Buy
Cialis Generic	5mg	10 Pills	29.39€ 27.99€	Buy
Cialis Generic	20mg	180 + 10 Pills	254.09€ 241.99€	Buy

When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. Clinical pharmacology studies have been conducted with coadministration of tadalafil with doxazosin, alfuzosin or tamsulosin [see Clinical Pharmacology (12.2)].7.3 AntihypertensivesPDE5 inhibitors, including tadalafil tablets, are mild systemic vasodilators. Small reductions in blood pressure occurred following coadministration of tadalafil with these cialis professional order agents compared with placebo [see Clinical Pharmacology (12.2)].7.4 AlcoholBoth alcohol and tadalafil, a PDE5 inhibitor, act as mild vasodilators. When mild vasodilators are taken in combination, blood pressure–lowering effects of each individual compound may be increased. Substantial consumption of alcohol (e.g., 5 units or greater) in combination with tadalafil tablets can increase the potential for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.

Risks and warnings for Tadalafil (Cialis)

Substantial consumption of alcohol (e.g., 5 units or greater) in combination with tadalafil tablets can increase the potential for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, dizziness, and headache. Tadalafil (10 mg or 20 mg) did not affect alcohol plasma concentrations and alcohol did not affect tadalafil plasma concentrations. [See Clinical Pharmacology (12.2)].7.5 CYP3A Inhibitors/InducersRitonavirRitonavir initially inhibits and later induces CYP3A, the enzyme involved in the metabolism of tadalafil. At steady state of ritonavir (about 1 week), the exposure to tadalafil is similar as in the absence of ritonavir [see Dosage and Administration (2.4), and Clinical Pharmacology (12.3)].Potent Inhibitors of CYP3ATadalafil is metabolized predominantly by CYP3A in the liver. In patients taking potent inhibitors of CYP3A such as ketoconazole, and itraconazole, avoid use of tadalafil tablets [see Clinical Pharmacology (12.3)].Potent Inducers of CYP3AFor patients chronically taking potent inducers of CYP3A, such as rifampin, avoid use of tadalafil tablets [see Clinical Pharmacology (12.3)].

Check with your doctor if you have or have had:

Administration of nitrates within 48 hours after the last dose of tadalafil is contraindicated [see Contraindications (4.1)]. PDE5 inhibitors, including tadalafil tablets, and alpha–adrenergic blocking agents are both vasodilators with blood-pressure-lowering effects. Clinical pharmacology studies have been conducted with coadministration of tadalafil with doxazosin, alfuzosin or tamsulosin [see Clinical Pharmacology (12.2)]. PDE5 inhibitors, including tadalafil tablets, are mild systemic vasodilators. Small reductions in blood pressure occurred following coadministration of tadalafil with these agents compared with placebo [see Clinical Pharmacology (12.2)].

Cialis for benign prostatic hyperplasia (BPH)

Both alcohol and tadalafil, a PDE5 inhibitor, act as mild vasodilators. Ritonavir initially inhibits and later induces CYP3A, the enzyme involved in the metabolism of tadalafil. At steady state of ritonavir (about 1 week), the exposure to tadalafil is similar as in the absence of ritonavir [see Dosage and Administration (2.4), and Clinical Pharmacology (12.3)]. Tadalafil is metabolized predominantly by CYP3A in the liver. In patients taking potent inhibitors of CYP3A such as ketoconazole, and itraconazole, avoid use of tadalafil tablets [see Clinical Pharmacology (12.3)]. Tadalafil (10 mg or 20 mg) did not affect alcohol plasma concentrations and alcohol did not affect tadalafil plasma concentrations. [See Clinical Pharmacology (12.2)].7.5 CYP3A Inhibitors/InducersRitonavirRitonavir initially inhibits and later induces CYP3A, the enzyme involved in the metabolism of tadalafil.

Dosage (mg)	Tablet Description	Recommended Use	Onset Time	Duration of Effect
2.5	Small white pill	Daily use for erectile dysfunction	30-60 min	Up to 24 hours
5	Small white pill	Daily use, mild to moderate cases	30-60 min	Up to 36 hours
10	White oval pill	As-needed basis, moderate cases	30 min	Up to 36 hours
20	White oval pill	As-needed basis, severe cases	30 min	Up to 36 hours

At steady state of ritonavir (about 1 week), the exposure to tadalafil is similar as in the absence of ritonavir [see Dosage and Administration (2.4), and Clinical Pharmacology (12.3)].Potent Inhibitors of CYP3ATadalafil is metabolized predominantly by CYP3A in the liver. In patients taking potent inhibitors of CYP3A such as ketoconazole, and itraconazole, avoid use of tadalafil tablets [see Clinical Pharmacology (12.3)].Potent Inducers of CYP3AFor patients chronically taking potent inducers of CYP3A, such as rifampin, avoid use of tadalafil tablets [see Clinical Pharmacology (12.3)].

• The pill's white color may help in distinguishing it from other medications.
• Some white Cialis pills are scored for easy splitting if prescribed in a lower dose.
• Never crush or break pills unless explicitly advised by a healthcare professional.

Administration of nitrates within 48 hours after the last dose of tadalafil is contraindicated [see Contraindications (4.1)].

Interactions between Tadalafil (Cialis) and other drugs

PDE5 inhibitors, including tadalafil tablets, and alpha–adrenergic blocking agents are both vasodilators with blood-pressure-lowering effects. Clinical pharmacology studies have been conducted with coadministration of tadalafil with doxazosin, alfuzosin or tamsulosin [see Clinical Pharmacology (12.2)]. PDE5 inhibitors, including tadalafil tablets, are mild systemic vasodilators.

Side Effects

Small reductions in blood pressure occurred following coadministration of tadalafil with these agents compared with placebo [see Clinical Pharmacology (12.2)]. Both alcohol and tadalafil, a PDE5 inhibitor, act as mild vasodilators.

Tadalafil price More Price(81)

For patients chronically taking potent inducers of CYP3A, such as rifampin, avoid use of tadalafil tablets [see Clinical Pharmacology (12.3)]. 8 USE IN SPECIFIC POPULATIONS 8.1 PregnancyRisk SummaryLimited data from case series with tadalafil use in pregnant women have not generic cialis 10 pills identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal reproduction studies, no adverse developmental effects were observed with oral administration of tadalafil to pregnant rats or mice during organogenesis at exposures 7 times the exposure at the maximum recommended human dose (MRHD) of 40 mg/day based on AUC (see Data).The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S.

What does TADALAFIL (Generic for ADCIRCA) look like?

general population, the background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.Clinical ConsiderationsDisease-Associated Maternal and/or Embryo/Fetal RiskPregnant women with untreated pulmonary arterial hypertension are at risk for heart failure, stroke, preterm delivery, and maternal and fetal death.DataAnimal DataTadalafil and/or its metabolites cross the placenta, resulting in fetal exposure in rats.Animal reproduction studies showed no evidence of teratogenicity, embryotoxicity, or fetotoxicity when tadalafil was given to pregnant rats or mice at unbound tadalafil exposures up to 7 times the exposure at the maximum recommended human dose (MRHD) of 40 mg/day during organogenesis based on AUC. In one of two perinatal/postnatal developmental studies in rats, a reduction of postnatal pup survival was observed at dose levels of 60, 200 and 1000 mg/kg. The no-observed-effect-level (NOEL) for developmental toxicity was 30 mg/kg, which provided maternal exposure to unbound tadalafil concentrations approximately 5 times the exposure at the MRHD based on AUC. Signs of maternal toxicity occurred at doses greater than 200 mg/kg/day, which produced AUCs greater than 8 times the exposure at the MRHD. Surviving offspring had normal development and reproductive performance.8.2 LactationRisk SummaryThere are no data on the presence of tadalafil and/or its metabolites in human milk, the effects on the breastfed child, or the effects on milk production.

Overall Rating

Tadalafil and/or its metabolites are present in the milk of lactating rats at concentrations approximately 2.4-times that found in the plasma. When a drug is present in animal milk, it is likely that the drug will be present in human milk.The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for tadalafil tablets and any potential adverse effects on the breastfed child from tadalafil tablets or from the underlying maternal condition.8.3 Females and Males of Reproductive PotentialInfertilityMalesBased on the data from 3 studies in adult males, tadalafil decreased sperm concentrations in the study of 10 mg tadalafil for 6 months and the study of 20 mg tadalafil for 9 months. This effect was not seen in the study of 20 mg tadalafil taken for 6 months. The clinical significance of the decreased sperm concentrations in the two studies is unknown. There have been no studies evaluating the effect of tadalafil on fertility in men or women [see Clinical Pharmacology (12.2)].8.4 Pediatric UseSafety and effectiveness of tadalafil tablets in pediatric patients have not been established.8.5 Geriatric UseOf the total number of subjects in the clinical study of tadalafil for pulmonary arterial hypertension, 28 percent were 65 and over, while 8 percent were 75 and over. Ritonavir initially inhibits and later induces CYP3A, the enzyme involved in the metabolism of tadalafil. At steady state of ritonavir (about 1 week), the exposure to tadalafil is similar as in the absence of ritonavir [see Dosage and Administration (2.4), and Clinical Pharmacology (12.3)]. Tadalafil is metabolized predominantly by CYP3A in the liver.

Country	Cost per 10 pills (USD)	Availability (OTC/Prescription)	Generic Options Available
United States	300	Prescription only	Yes
United Kingdom	150	Prescription only	Yes
Canada	200	Prescription only	Yes
India	40	OTC or Prescription	Yes
Australia	180	Prescription only	Limited
Germany	160	Prescription only	Yes

In patients taking potent inhibitors of CYP3A such as ketoconazole, and itraconazole, avoid use of tadalafil tablets [see Clinical Pharmacology (12.3)]. For patients chronically taking potent inducers of CYP3A, such as rifampin, avoid use of tadalafil tablets [see Clinical Pharmacology (12.3)].

• The active ingredient tadalafil in white Cialis inhibits PDE5 enzymes.
• This process helps relax blood vessels and increases blood flow to the penis.
• White Cialis does not cause an instant erection; sexual stimulation is also necessary.

8 USE IN SPECIFIC POPULATIONS 8.1 PregnancyRisk SummaryLimited data from case series with tadalafil use in pregnant women have not generic cialis 10 pills identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal reproduction studies, no adverse developmental effects were observed with oral administration of tadalafil to pregnant rats or mice during organogenesis at exposures 7 times the exposure at the maximum recommended human dose (MRHD) of 40 mg/day based on AUC (see Data).The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S.

4.2 Concomitant Guanylate Cyclase (GC) Stimulators

No overall differences in safety were observed between subjects over 65 years of age compared to younger subjects or those over 75 years of age. No dose adjustment is warranted based on age alone; however, a greater sensitivity to medications in some older individuals should be considered. [See Clinical Pharmacology (12.3)].8.6 Renal ImpairmentFor patients with mild or moderate renal impairment, start tadalafil tablets at 20 mg once daily. Increase the dose to 40 mg once daily based upon individual tolerability [see Dosage and Administration (2.2), and Clinical Pharmacology (12.3)].In patients with severe renal impairment, avoid use of tadalafil tablets because of increased tadalafil exposure (AUC), limited clinical experience, and the lack of ability to influence clearance by dialysis [see Clinical Pharmacology (12.3)].8.7 Hepatic ImpairmentBecause of limited clinical experience in patients with mild to moderate hepatic cirrhosis (Child-Pugh Class A or B), consider a starting dose of tadalafil tablets 20 mg once daily.

What CIALIS looks like

Alternatives for benign prostatic hyperplasia (BPH)

general population, the background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.Clinical ConsiderationsDisease-Associated Maternal and/or Embryo/Fetal RiskPregnant women with untreated pulmonary arterial hypertension are at risk for heart failure, stroke, preterm delivery, and maternal and fetal death.DataAnimal DataTadalafil and/or its metabolites cross the placenta, resulting in fetal exposure in rats.Animal reproduction studies showed no evidence of teratogenicity, embryotoxicity, or fetotoxicity when tadalafil was given to pregnant rats or mice at unbound tadalafil exposures up to 7 times the exposure at the maximum recommended human dose (MRHD) of 40 mg/day during organogenesis based on AUC. In one of two perinatal/postnatal developmental studies in rats, a reduction of postnatal pup survival was observed at dose levels of 60, 200 and 1000 mg/kg. The no-observed-effect-level (NOEL) for developmental toxicity was 30 mg/kg, which provided maternal exposure to unbound tadalafil concentrations approximately 5 times the exposure at the MRHD based on AUC. Signs of maternal toxicity occurred at doses greater than 200 mg/kg/day, which produced AUCs greater than 8 times the exposure at the MRHD. Surviving offspring had normal development and reproductive performance.8.2 LactationRisk SummaryThere are no data on the presence of tadalafil and/or its metabolites in human milk, the effects on the breastfed child, or the effects on milk production. Tadalafil and/or its metabolites are present in the milk of lactating rats at concentrations approximately 2.4-times that found in the plasma. When a drug is present in animal milk, it is likely that the drug will be present in human milk.The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for tadalafil tablets and any potential adverse effects on the breastfed child from tadalafil tablets or from the underlying maternal condition.8.3 Females and Males of Reproductive PotentialInfertilityMalesBased on the data from 3 studies in adult males, tadalafil decreased sperm concentrations in the study of 10 mg tadalafil for 6 months and the study of 20 mg tadalafil for 9 months.

• The onset of action for white Cialis is typically around 30 minutes after ingestion.
• The duration of effects can help plan spontaneous sexual activity.
• It is important to follow prescribed instructions for safe usage.

This effect was not seen in the study of 20 mg tadalafil taken for 6 months.

4.3 Hypersensitivity Reactions

In the placebo-controlled study, the most common AEs were generally transient and mild to moderate in intensity. Table 1 presents treatment-emergent adverse events reported by greater than or equal to 9% of patients in the tadalafil tablets 40 mg group and occurring more frequently than with placebo. The following adverse reactions have been identified during post-approval use of tadalafil. The list does not include adverse events that are reported from clinical trials and that are listed elsewhere in this section. Cardiovascular and cerebrovascular — Serious cardiovascular events, including myocardial infarction, sudden cardiac death, stroke, chest pain, palpitations, and tachycardia, have been reported postmarketing in temporal association with the use of tadalafil [see Contraindications (4.1)].

For BPH

It is not possible to determine whether these events are related directly to tadalafil, to sexual activity, to the patient’s underlying cardiovascular disease, to a combination of these factors, or to other factors. Body as a whole — Hypersensitivity reactions including urticaria, Stevens–Johnson syndrome, and exfoliative dermatitis Nervous — Migraine, seizure and seizure recurrence, and transient global amnesia Ophthalmologic — Visual field defect, retinal vein occlusion, retinal artery occlusion, and NAION [see Warnings and Precautions (5.3) and Patient Counseling Information (17)]. Otologic — Cases of sudden decrease or loss of hearing have been reported postmarketing in temporal association with the use of PDE5 inhibitors, including tadalafil. It is not possible to determine whether these reported events are related directly to the use of tadalafil, to the patient’s underlying risk factors for hearing loss, a combination of these factors, or to other factors [see Warnings and Precautions (5.4) and Patient Counseling Information (17)]. Urogenital — Priapism [see Warnings and Precautions (5.6)].

How are Cialis and Viagra different?

7 DRUG INTERACTIONS 7.1 NitratesAdministration of nitrates within 48 hours after the last dose of tadalafil is contraindicated [see Contraindications (4.1)].7.2 Alpha-BlockersPDE5 inhibitors, including tadalafil tablets, and alpha–adrenergic blocking agents are both vasodilators with blood-pressure-lowering effects. When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. Clinical pharmacology studies have been conducted with coadministration of tadalafil with doxazosin, alfuzosin or tamsulosin [see Clinical Pharmacology (12.2)].7.3 AntihypertensivesPDE5 inhibitors, including tadalafil tablets, are mild systemic vasodilators. Small reductions in blood pressure occurred following coadministration of tadalafil with these cialis professional order agents compared with placebo [see Clinical Pharmacology (12.2)].7.4 AlcoholBoth alcohol and tadalafil, a PDE5 inhibitor, act as mild vasodilators. When mild vasodilators are taken in combination, blood pressure–lowering effects of each individual compound may be increased. The clinical significance of the decreased sperm concentrations in the two studies is unknown. There have been no studies evaluating the effect of tadalafil on fertility in men or women [see Clinical Pharmacology (12.2)].8.4 Pediatric UseSafety and effectiveness of tadalafil tablets in pediatric patients have not been established.8.5 Geriatric UseOf the total number of subjects in the clinical study of tadalafil for pulmonary arterial hypertension, 28 percent were 65 and over, while 8 percent were 75 and over. No overall differences in safety were observed between subjects over 65 years of age compared to younger subjects or those over 75 years of age. No dose adjustment is warranted based on age alone; however, a greater sensitivity to medications in some older individuals should be considered. [See Clinical Pharmacology (12.3)].8.6 Renal ImpairmentFor patients with mild or moderate renal impairment, start tadalafil tablets at 20 mg once daily. Increase the dose to 40 mg once daily based upon individual tolerability [see Dosage and Administration (2.2), and Clinical Pharmacology (12.3)].In patients with severe renal impairment, avoid use of tadalafil tablets because of increased tadalafil exposure (AUC), limited clinical experience, and the lack of ability to influence clearance by dialysis [see Clinical Pharmacology (12.3)].8.7 Hepatic ImpairmentBecause of limited clinical experience in patients with mild to moderate hepatic cirrhosis (Child-Pugh Class A or B), consider a starting dose of tadalafil tablets 20 mg once daily.

Copyright ©  後藤純男美術館

PAGE TOP